Combining Cabometyx (cabozantinib) with Opdivo (nivolumab) significantly extends survival, delays disease progression and increases the rate of positive responses compared to standard treatment with Sutent (sunitinib) among people with newly diagnosed advanced renal cell cancer, a pivotal Phase 3 trial shows. The recent findings mean that the CheckMate -9ER trial (NCT03141177) met its primary goal of extending life without disease worsening, as well the secondary objectives of overall survival and increasing treatment responses. “[W]e look forward to…
April 29, 2020April 29, 2020